Skip to content
TriangleGet started
← Back to this collection

PUBLICATIONS · 31868632

Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet
Publication date
2019 Dec 21
First author
Poeschel V

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2020 Dec 21;394(10216):2208-2209. doi: 10.1016/S0140-6736(19)33105-8.
    note
    Source null
    related pmid
    31868615
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2020 Mar;17(3):135. doi: 10.1038/s41571-020-0326-x.
    note
    Source null
    related pmid
    31925412
    relationship
    Comment in

Authors and identifiers

  1. name
    Poeschel V
    type
    Author
  2. name
    Held G
    type
    Author
  3. name
    Ziepert M
    type
    Author
  4. name
    Witzens-Harig M
    type
    Author
  5. name
    Holte H
    type
    Author
  6. name
    Thurner L
    type
    Author
  7. name
    Borchmann P
    type
    Author
  8. name
    Viardot A
    type
    Author
  9. name
    Soekler M
    type
    Author
  10. name
    Keller U
    type
    Author
  11. name
    Schmidt C
    type
    Author
  12. name
    Truemper L
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Poeschel V
    type
    Author
  2. name
    Held G
    type
    Author
  3. name
    Ziepert M
    type
    Author
  4. name
    Witzens-Harig M
    type
    Author
  5. name
    Holte H
    type
    Author
  6. name
    Thurner L
    type
    Author
  7. name
    Borchmann P
    type
    Author
  8. name
    Viardot A
    type
    Author
  9. name
    Soekler M
    type
    Author
  10. name
    Keller U
    type
    Author
  11. name
    Schmidt C
    type
    Author
  12. name
    Truemper L
    type
    Author
bibliography ids
  1. nci-bib-b5872e0d39254847b3078d18
book metadata
content sha256
41cc4443f80bb1a3a34d2f166fbaa896e39c95aaf3fbd74497880b1c8f4e9eca
document type
citation
dois
  1. 10.1016/S0140-6736(19)33008-9
electronic publication date
display
Source null
precision
missing
year
Source null
evidence scope
bibliographic_metadata_only
id
pubmed:31868632
immutable id
pubmed:31868632@41cc4443f80bb1a3a34d2f166fbaa896e39c95aaf3fbd74497880b1c8f4e9eca
journal
abbreviation
Lancet
issn electronic
1474-547X
issn print
0140-6736
issue
10216
name
Lancet (London, England)
nlm unique id
2985213R
pages
2271-2281
volume
394
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet. 2020 Dec 21;394(10216):2208-2209. doi: 10.1016/S0140-6736(19)33105-8.
    note
    Source null
    related pmid
    31868615
    relationship
    Comment in
  2. citation
    Nat Rev Clin Oncol. 2020 Mar;17(3):135. doi: 10.1038/s41571-020-0326-x.
    note
    Source null
    related pmid
    31925412
    relationship
    Comment in
outcomes validated
false
pmid
31868632
provenance
batch id
4c5003fbb78890e89ae1
provider
NCBI PubMed ESummary
record sha256
539aaa95218ae2b65303ce3bfe1cbd1da7ee4464bcb3168c5767c53d4c1fbde6
response sha256
890389583ce193a9c74e19c63678e418dad2088e82cb704b888b02fcc887d269
retrieved at
2026-09-09T23:47:48.270700+00:00
publication date
display
2019 Dec 21
precision
day
year
2019
publication types
  1. Clinical Trial, Phase III
  2. Comparative Study
  3. Equivalence Trial
  4. Journal Article
  5. Multicenter Study
  6. Randomized Controlled Trial
  7. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/31868632/
title
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.

Preserved source evidence · Independent clinical review pending · Not medical advice